Home > Insider Trading > Filing (0000950170-24-043503)

Filing Details

Accession Number:: 0000950170-24-043503
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-04-10 20:53:46
Reporting Period:: 2024-04-08

Accepted Time:: 2024-04-10 20:53:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1157601	Madrigal Pharmaceuticals Inc.	MDGL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1423898	Rebecca Taub	C/O Madrigal Pharmaceuticals, Inc. 200 Barr Harbor Drive, Suite 400 West Conshohocken PA 19428	Pres., R&D, And Cmo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-04-08	2,676	$9.45	461,675	No	4	M	Direct
Common Stock	Disposition	2024-04-08	224	$243.25	461,451	No	4	S	Direct
Common Stock	Disposition	2024-04-08	945	$244.79	460,506	No	4	S	Direct
Common Stock	Disposition	2024-04-08	300	$245.69	460,206	No	4	S	Direct
Common Stock	Disposition	2024-04-08	600	$246.98	459,606	No	4	S	Direct
Common Stock	Disposition	2024-04-08	407	$247.76	459,199	No	4	S	Direct
Common Stock	Disposition	2024-04-08	200	$248.58	458,999	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-04-08	2,676	$0.00	2,676	$9.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
76,564		2026-07-22	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	655,540	Indirect	By SQN LLC

Footnotes

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $243.12 to $243.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $244.37 to $245.24, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $245.38 to $246.13, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $246.50 to $247.25, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $247.56 to $248.5150, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.57 to $248.59, inclusive.
The Reporting Person and her spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The shares underlying this stock option are fully vested and exercisable.